TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01508325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (\>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was \>=90 mmHg measured every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was \>=140 mmHg and/or DBP was \>=90 mmHg measured every 4 weeks.
Study: NCT02061709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ragweed-SPIRE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ragweed-SPIRE
Study: NCT02266784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)

Intervention type: DRUG
Group type: OTHER
Intervention: Transdermal nicotine skin patches (i.e. Habitrol)

Intervention type: OTHER
Group type: OTHER
Intervention: Supportive Counseling
Study: NCT04204109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interprofessional case-based learning
Description: The trial is an educational intervention where groups of healthcare professionals receive the same case-based learning: one group receives case-based learning with healthcare professionals of various professional backgrounds (experimental) versus another group receiving case-based learning with healthcare professionals exclusively of the same professional background (control).~The educational intervention consists of a case that is developed for the purpose of the intervention.~The participants in the experimental group will be randomised into six teams who will receive interprofessional case-based learning. The experimental group will be made up of healthcare professionals from various groups. The participants in the control group will be randomised in groups of one profession

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interprofessional case-based learning
Description: The trial is an educational intervention where groups of healthcare professionals receive the same case-based learning: one group receives case-based learning with healthcare professionals of various professional backgrounds (experimental) versus another group receiving case-based learning with healthcare professionals exclusively of the same professional background (control).~The educational intervention consists of a case that is developed for the purpose of the intervention.~The participants in the experimental group will be randomised into six teams who will receive interprofessional case-based learning. The experimental group will be made up of healthcare professionals from various groups. The participants in the control group will be randomised in groups of one profession
Study: NCT01648699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osmotic Release Oral System (OROS) hydromorphone
Description: OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
Study: NCT06585189

Intervention type: DRUG
Intervention: Pembrolizumab
Study: NCT02061709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ragweed-SPIRE

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06585189

Intervention type: DRUG
Intervention: Pemetrexed
Study: NCT01831518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT Implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Surface ECG Mapping
Study: NCT04074733

Intervention type: DIAGNOSTIC_TEST
Intervention: Patient undergoes a ULD scan
Description: The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis

Intervention type: DIAGNOSTIC_TEST
Intervention: Patient undergoes a standard X-ray
Description: The following doses will be applied:~For the pelvis : front view and profile for the hip. For the dorsal spine : front and profile. For the lumbar spine : front and profile For the extremities : front and profile

Intervention type: DIAGNOSTIC_TEST
Intervention: Patient undergoes a classic-dose scan
Description: The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis
Study: NCT02805920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: comparison of different volumes-dosages of 0.25% Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: comparison of different volumes-dosages of 0.25% Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: comparison of different volumes-dosages of 0.25% Bupivacaine
Study: NCT02640664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
Study: NCT01683318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal Pulsation therapy
Study: NCT02170220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets
Study: NCT03678610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doing ICSI I a medium supplemented with Ionomycin and Latrunculin A
Description: Ionomycin and Latrunculin A would activate oocyte during ICSI along with cytoskeleton stabilization for a favourable outcomes
Study: NCT02241200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA3880
Study: NCT04242940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitting of Ponto 4
Description: Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting one/two bone-anchored sound processors (Ponto 4) to patients that are already implanted with abutments.
Study: NCT04377204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marcaine bupivacaine
Description: This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
Study: NCT00997841

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-Care versus conventional coagulation management
Description: Patients are randomized to receive either point-of-care based or conventional coagulation measurements based coagulation therapy in the case of increased perioperative bleeding tendency

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-Care versus conventional coagulation management
Description: Patients are randomized to receive either point-of-care based or conventional coagulation measurements based coagulation therapy in the case of increased perioperative bleeding tendency
Study: NCT01105169

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium glycinate
Description: Oral administration of magnesium glycinate daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium glycinate
Description: Oral administration of magnesium glycinate daily for 12 weeks
Study: NCT00746603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
Study: NCT01105169

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of identical-appearing placebo daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of identical-appearing placebo daily for 12 weeks
Study: NCT02069600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: CPAP applies a positive pressure into the airway to avoid its collapse during sleep.~The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing
Study: NCT02814604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Rating Systems
Description: Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Rating Systems
Description: Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Rating Systems
Description: Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.
Study: NCT01827111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
Study: NCT03860194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protison with High Protein 51(Original Flavor)
Description: Contents of each supplement sachet has a calorie of 88 kcal, 12.8 g protein( including 8.5 g whey protein concentrate), 1.2 g leucine, 7.3 g carbohydrates, 0.8 g fat and 120 IU vitamin D per serving. This supplement was added 200 ml water and stirred well, then drank before meal.
Study: NCT05090072

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advance Directives
Description: The palliative care physician engaged patients and their caregivers in an open discussion about patients' answers to the Advance Directives document, to explore and clarify all doubts and questions prompted by the document

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The palliative care physician undergone a conference with both patients and caregivers and evaluated patients' symptoms using the the Edmonton Frail Scale (Bruera, 1991), adapted to the Portuguese population. The Advance Directives theme wasn't approached during this conference.
Study: NCT01827111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
Study: NCT03983525

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goji berry
Description: Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take 28 grams of goji berry once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein + zeaxanthin supplementation
Description: Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take one capsule of lutein + zeaxanthin supplementation once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
Study: NCT03591848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online support decision tool
Description: Online support decision tool, in addition of the standard oral information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard oral information
Description: standard oral information

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard oral information
Description: standard oral information
Study: NCT02925962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS)
Description: A targeted, automated CKD clinical decision support system (CDSS) designed to improve bloodpressure (BP) level, disease awareness, staging, processes of care, and knowledge among persons with documented reduced eGFRcreat (creatinine-based estimated glomerular filtration rate) in primary care setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinic Decision Sup System + Pharmacist
Description: Includes everything in the CDSS intervention but adds a follow-up call from a pharmacist, who is part of the clinical team. The rationale for this third arm is based on the evidence that clinical pharmacists have been shown to be more effective than physicians alone at achieving BP control in other settings.
Study: NCT04153461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MINI-PERCUTANEOUS NEPHROLITHOTOMY
Description: MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
Study: NCT06585189

Intervention type: DRUG
Intervention: Cisplatin

Intervention type: DRUG
Intervention: Cisplatin

Intervention type: DRUG
Intervention: Carboplatin
Study: NCT04153461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD PERCUTANEOUS NEPHROLITHOTOMY
Description: PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
Study: NCT06585189

Intervention type: DRUG
Intervention: Carboplatin
Study: NCT01531478

Intervention type: OTHER
Intervention: Unique medical visit of the study
Description: The visit will be with an oncologist specialized in the long-term follow-up of cured pediatric cancer patients. The examination will consist in weight and height measurements, a clinical examination and a measurement of arterial pressure. The list of drugs taken in the last two years, as well as all health issues encountered since the cancer treatment, will be collected. Success in education, career and, family status will also be discussed.~After the medical examination, patients will be offered a visit with a psychologist in order to assess their psychopathological outcomes. This questionnaire is a interquestionnaire designed to screen axis I psychopathological conditions. It includes an evaluation of all types of risk-taking behavior (alcohol, drugs, anorexia and bulimia).
Study: NCT01536795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR279,396 with Tegaderm Dressing
Description: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279,396 with Gauze and Tape Dressing
Description: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
Study: NCT06119776

Intervention type: PROCEDURE
Intervention: Whipple over the splenic artery
Description: Treatment for pancreatic ductal cell adenocarcinoma

Intervention type: PROCEDURE
Intervention: Total pancreatectomy
Description: Treatment for pancreatic ductal cell adenocarcinoma
Study: NCT02549781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Go-Nogo test
Description: In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Go-Nogo test
Description: In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Go-Nogo test
Description: In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization.
Study: NCT01779843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Study: NCT02445820

Intervention type: DRUG
Intervention: HES
Description: 2500 mL of balanced HES 130/0.4

Intervention type: DRUG
Intervention: Crystalloid
Description: 2500 mL of balanced crystalloid.
Study: NCT01665235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI / ARB
Description: ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin or Clopidogrel
Description: aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin or Clopidogrel
Description: aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10 - 40mg / d ( statin therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10 - 40mg / d ( statin therapy)
Study: NCT00171977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Study: NCT04915469

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized enhanced adherence counseling package
Description: A standardized package was developed to support the adherence counsellor and other cadres to ensure provision of quality EAC sessions for children, adolescents and their caregivers. The package included; 1) Orientation and on job mentorship on EAC processes to clinicians, nurses, peer educators and mentor mothers. 2) Using a communication's training curriculum, providers were trained on psychosocial support and communication skills for children and their caregivers. 3) Appointment management was done using appointment dairies or a digital platform that sends patients short message services (SMS) reminders 3 days and 1 day before a scheduled clinic day. 4)Home visits. - All home visits were done according to the EGPAF standard operation procedures (SOPs) drawn from the Kenya National guidelines. 5) Individualized case management -Each EAC client was allocated a case manager who ensured that the barriers to adherence were identified and tackled both at individual and community level.
Study: NCT01853150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS Motor cortex

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS Supplementary motor area
Study: NCT00363766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636-sodium
Description: A loading dose to target 420 micrograms/milliliter (µg/mL) maximum concentration (Cmax) or 380 µg/mL Cmax followed by a lower chronic dose to maintain Cmax within these target ranges, intravenous, every 21 days until disease progression.
Study: NCT02798198

Intervention type: OTHER
Intervention: T2DM
Description: T2DM without DKD